Useful Resources: Mayo Clinic Semaglutide NIH Diabetes Treatment Options CDC Managing Diabetes Patient Education Materials Diabetes.org: Patient-friendly information about GLP-1 agonist side effects CDC Diabetes Prevention Program: Lifestyle modification resources Academy of Nutrition and Dietetics: Evidence-based nutrition guidance Emergency Resources Poison Control: 1-800-222-1222 for medication-related emergencies American Association of Poison Control Centers: 24/7 emergency guidance Local Emergency Services: 911 for severe side effects requiring immediate attention Professional Organizations American College of Physicians: Clinical practice guidelines Endocrine Society: Hormone and metabolism expertise American Board of Family Medicine: Family medicine resources Mobile Apps and Tools MyFitnessPal: Nutrition tracking to support medication effectiveness Glucose monitoring apps: For patients with diabetes Medication reminder apps: To maintain consistent dosing schedules Clinical Trial Information ClinicalTrials.gov: Current research on semaglutide and GLP-1 agonists National Institute of Health: Research updates and findings Note: Always consult with your healthcare provider before using any resources or making treatment decisions based on online information

If youre ever unsure about how to use an injection pen or what the appropriate storage techniques for your medication are, refer back to this guide.
Semaglutide is the active ingredient in three FDA-approved prescription medications: Ozempic and Rybelsus, approved for improving blood sugar control in adults with type 2 diabetes, and Wegovy, approved for chronic weight management in adults with obesity or overweight who have at least one weight-related medical condition
Once a shortage ends, that changes
Non-GLP-1 alternatives If GLP-1 medications are too expensive, there are more affordable alternatives that can still help you lose weight and maintain the weight loss
Other physiological parameters, including systolic blood pressure, BMI, and cholesterol, were assumed to remain constant following the application of initial treatment effects while patients received oral semaglutide or liraglutide (in line with relatively long-term data of GLP-1 receptor agonists) [12, 13]